Trexquant Investment’s Monte Rosa Therapeutics GLUE Stock Holding History

Trexquant Investment’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.79M	Buy	115,363 +66,184	+135%	+$1.25M	0.02%	1042
2026 Q1	$809K	Sell	49,179 -100,533	-67%	-$1.92M	0.01%	1306
2025 Q4	$2.35M	Buy	+149,712	New	+$2.02M	0.02%	934
2025 Q2	–	Sell	-26,188	Closed	-$122K	–	1656
2025 Q1	$122K	Buy	+26,188	New	+$161K	﹤0.01%	1494
2023 Q4	–	Sell	-25,657	Closed	-$123K	–	1560
2023 Q3	$123K	Buy	25,657 +10,935	+74%	+$70.4K	﹤0.01%	1387
2023 Q2	$101K	Sell	14,722 -7,003	-32%	-$45.3K	﹤0.01%	1371
2023 Q1	$169K	Buy	21,725 +4,791	+28%	+$33.3K	﹤0.01%	1347
2022 Q4	$129K	Sell	16,934 -24,666	-59%	-$205K	﹤0.01%	1298
2022 Q3	$340K	Buy	+41,600	New	+$382K	0.01%	969

Other funds holding GLUE

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trexquant Investment's GLUE Position: Q2 2026 in Review

Trexquant Investment increased its Monte Rosa Therapeutics (GLUE) stake by 135% in Q2 2026, buying an estimated $1.25M and bringing the position to 115,363 shares worth $2.79M. The position accounts for 0.02% of the portfolio, ranked #1042.

Trexquant Investment first reported a position in GLUE in Q3 2022 and has held it in 9 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

Trexquant Investment held 115,363 shares of Monte Rosa Therapeutics worth $2.79M as of Q2 2026.
Trexquant Investment bought 66,184 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.25M.
Monte Rosa Therapeutics made up 0.02% of Trexquant Investment's portfolio in Q2 2026, its #1042 holding.
Trexquant Investment first reported a position in Monte Rosa Therapeutics in Q3 2022 and has held it in 9 quarters since.
193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.